FGI-106

Research use only, not for human use.

FGI-106 is a broad-spectrum inhibitor of multiple blood-borne viruses (HCV, HBV, HIV) as well as emerging biothreats.

FGI-106 is a broad-spectrum inhibitor of multiple blood-borne viruses (HCV, HBV, HIV) as well as emerging biothreats (Ebola, VEE, Cowpox, PRRSV infection) with EC50 of 0.2-10 uM; inhibits the interaction of TSG101 with its cognate viral ligands; displays an ability to prevent lethality from Ebola in vivo; well-tolerated and orally bioavailable.

Treatment with 2 μM FGI-106 mediated a 4 log reduction in infectious viral titers relative to matched controls, with an EC90 for inhibition of viral killing of host cells (Vero E6 cells) estimated to be 0.6 μM.In cell-based assays, treatment with FGI-106 inhibits viral replication by divergent virus families, including positive and negative-strand RNA viruses.

FGI-106 (0.1-5 mg/kg; intraperitoneal injection; treatments on days 2 and 5; C57BL/6 or BALB/c mice) treatment decreases mortality from Zaire EBOV in a dose-dependent manner. Animal Model:Male or female C57BL/6 or BALB/c mice (6-10 weeks of age) injected with EBOV (Ebola virus) Dosage:0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 5 mg/kg Administration:Intraperitoneal injection; treatments on days 2 and 5 Result:Decreased mortality from Zaire EBOV in a dose-dependent manner.

FGI106

Microbiology/Virology

Filovirus

Filovirus

——

——

501081-38-5

458.654

C28H38N6

>98% (HPLC)

——

CC1=CC(=C2C=CC3=C(C2=N1)C=CC4=C(C=C(N=C34)C)NCCCN(C)C)NCCCN(C)C

Quino[8,7-h]quinoline-1,7-diamine, N,N'-bis[3-(dimethylamino)propyl]-3,8-dimethyl- (9CI)

(-20℃)

With Ice Pack

≥ 2 years